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Running	head:	Menopausal	hormone	therapy	and	upper	gastrointestinal	cancer	
	
Novelty	statement:	This	study	shows	that	users	of	menopausal	hormone	therapy	are	at	a	
decreased	risk	of	esophageal	and	gastric	cancer.	These	findings	may	be	due	to	sex	hormonal	
exposure.	
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ABSTRACT	
A	protective	effect	of	female	sex	hormones	has	been	suggested	to	explain	the	male	
predominance	in	esophageal	and	gastric	adenocarcinoma,	but	evidence	is	lacking.	We	
aimed	to	test	whether	menopausal	hormone	therapy	(MHT)	decreases	the	risk	of	these	
tumors.	For	comparison,	esophageal	squamous	cell	carcinoma	was	also	assessed.	This	
population-based	matched	cohort	study	included	all	women	who	had	ever	used	systemic	
MHT	in	Sweden	in	2005-2012.	A	comparison	cohort	of	non-users	of	MHT	was	matched	to	
the	MHT-users	regarding	age,	parity,	thrombotic	events,	hysterectomy,	diabetes,	obesity,	
smoking-related	diseases,	and	alcohol-related	diseases.	Individuals	with	any	previous	cancer	
were	excluded.	Data	on	MHT	use,	cancer,	comorbidity,	and	mortality	were	collected	from	
well-established	Swedish	nationwide	registers.	Odds	ratios	(OR)	with	95%	confidence	
intervals	(CI)	were	calculated	using	conditional	logistic	regression.	Different	MHT	regimens	
and	age	groups	were	compared	in	sub-group	analyses.	We	identified	290,186	ever-users	
and	870,165	non-users	of	MHT.	Ever-users	had	decreased	ORs	of	esophageal	
adenocarcinoma	(OR=0.62,	95%	CI	0.45-0.85,	n=46),	gastric	adenocarcinoma	(OR=0.61,	95%	
CI	0.50-0.74,	n=123),	and	esophageal	squamous	cell	carcinoma	(OR=0.57,	95%	CI	0.39-0.83,	
n=33).	The	ORs	were	decreased	for	both	estrogen-only	MHT	and	estrogen	and	progestin	
combined	MHT,	and	in	all	age	groups.	The	lowest	OR	was	found	for	esophageal	
adenocarcinoma	in	MHT-users	younger	than	60	years	(OR=0.20,	95%	CI	0.06-0.65).	Our	
study	suggests	that	MHT-users	are	at	a	decreased	risk	of	esophageal	and	gastric	
adenocarcinoma,	and	also	of	esophageal	squamous	cell	carcinoma.	The	mechanisms	behind	
these	associations	remain	to	be	elucidated.		 	
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INTRODUCTION	
The	explanation	for	the	intriguing	male	predominance	in	esophageal	and	gastric	
adenocarcinoma	might	provide	important	clues	to	the	etiology	of	these	tumors,	and	also	
pave	the	way	for	research	examining	novel	preventive	and	therapeutic	medication.1	The	up	
to	9-fold	higher	risk	of	esophageal	adenocarcinoma	among	men	than	in	women,	is	not	
explained	by	the	sex	distribution	of	its	main	risk	factors,	i.e.	gastroesophageal	reflux	disease	
and	obesity.1-5	For	gastric	adenocarcinoma,	the	incidence	is	2-fold	higher	in	men,	a	
difference	that	is	also	not	readily	explained	by	the	major	risk	factors,	i.e.	Helicobacter	pylori	
infection	and	tobacco	smoking.6-8	The	3-fold	higher	incidence	of	esophageal	squamous	cell	
carcinoma	in	men	is	mainly	explained	by	the	sex	distribution	of	its	main	risk	factors,	i.e.	
heavy	use	of	tobacco	and	alcohol.9,	10	Female	sex	hormones	may	prevent	esophageal	and	
gastric	adenocarcinoma.1,	6	However,	studies	examining	various	sex	hormone	related	
exposures	in	relation	to	risk	of	these	tumors	have	provided	conflicting	results.1,	6,	11	
Menopausal	hormone	therapy	(MHT),	also	known	as	hormone	replacement	therapy,	
consists	of	estrogen	or	estrogen	combined	with	progestin.	Original	studies	examining	MHT	
and	risk	of	esophageal	and	gastric	adenocarcinoma	have	typically	been	under-powered,	
have	mostly	examined	one	or	two	cancers	per	study,	and	arrived	at	inconsistent	findings.1,	11	
However,	meta-analyses	comparing	ever-users	of	MHT	with	non-users	have	shown	
statistically	significantly	decreased	relative	risk	estimates	of	esophageal	adenocarcinoma,	
gastric	adenocarcinoma,	and	also	of	esophageal	squamous	cell	carcinoma.12-14	We	
hypothesized	that	MHT	decreases	the	risk	of	esophageal	and	gastric	adenocarcinoma,	but	
not	of	esophageal	squamous	cell	carcinoma.	To	test	this	hypothesis	and	address	the	
limitations	of	the	available	literature,	we	conducted	a	large	and	population-based	study	
enabling	a	possibility	of	comparing	the	risks	of	all	three	cancers	in	one	study.	 	
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PATIENTS	AND	METHODS	
Design	
This	was	a	population-based	matched	cohort	study	based	on	prospectively	collected	data	
from	well-established	nationwide	Swedish	registers,	comparing	the	risk	of	esophageal	and	
gastric	cancer	in	all	women	residing	in	Sweden	exposed	to	systemic	MHT	with	that	of	
women	not	exposed	to	MHT.		Entry	into	the	cohort	was	between	July	1,	2005	and	December	
31,	2012.	Follow-up	for	both	the	users	and	non-	users	was	until	a	diagnosis	of	cancer,	death,	
or	December	31,	2012,	whichever	occurred	first.	The	non-users	of	MHT	were	frequency-
matched	to	the	ever-users	on	potential	confounding	factors.	Eligible	were	only	women	40	
years	or	older	without	any	previous	cancer.	The	study	was	approved	by	the	Regional	Ethical	
Review	Board	in	Stockholm,	Sweden	(number	2014/1291-31/4).	
	
Data	sources	
The	Swedish	Prescribed	Drug	Registry	was	used	to	identify	all	individuals	receiving	MHT	
during	the	study	period.	This	register	started	in	July	1,	2005,	and	collects	data	on	all	
prescribed	and	dispensed	drugs	in	Sweden,	including	the	names	of	medications,	Anatomical	
Therapeutic	Chemical	classification	system	(ATC)	codes,	and	the	dates	that	treatments	were	
dispensed.	Using	the	unique	10-digit	personal	identity	number,	assigned	to	all	Swedish	
residents	upon	birth	or	immigration,	all	included	women	were	linked	to	the	Swedish	Cancer	
Registry,	Patient	Registry,	and	the	Causes	of	Death	Registry.15	
	
The	Swedish	Cancer	Registry	contains	data	on	all	malignant	tumors	diagnosed	in	Sweden	
since	1958.	The	information	includes	date	of	diagnosis,	anatomical	site,	and	histological	type	
of	each	tumor.	The	register	has	98%	nationwide	completeness	regarding	both	esophageal	
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and	gastric	cancer,16,	17	and	the	recording	of	all	cancer	sites	is	96%	complete.18	This	register	
was	used	to	identify	esophageal	and	gastric	cancer	during	follow-up	of	the	ever-users	and	
non-users	of	MHT,	and	to	exclude	individuals	with	a	history	of	any	previous	cancer.	
	
The	Swedish	Patient	Registry	contains	information	regarding	diagnoses	and	surgical	
procedures	in	all	in-patient	care	and	specialist	out-patient	care	in	Sweden.	The	register	was	
founded	in	1964,	and	data	regarding	in-patient	care	and	out-patient	specialist	care	has	been	
100%	nationwide	complete	since	1987	and	2001,	respectively.19	The	validity	of	the	recording	
of	all	diagnoses	and	gynecological	surgical	procedures	is	excellent.19,	20	The	registry	was	used	
to	identify	comorbidities	used	in	the	matching	and	statistical	analyses.	Data	regarding	
comorbidities	were	retrieved	since	the	initiation	of	the	Patient	Registry	to	improve	
ascertainment	and	validity	of	comorbidities.	
	
The	Swedish	Causes	of	Death	Registry	contains	data	on	date	of	death	and	causes	of	death	of	
all	Swedish	residents	since	1952.	The	registry	has	an	overall	100%	completeness	regarding	
date	of	death	and	99.2%	completeness	for	cause-specific	death.21	This	register	was	used	to	
assess	mortality.		
	
Exposure	
The	MHT-exposed	cohort	included	all	women,	above	40	years	of	age	without	a	history	of	
any	cancer,	who	were	ever	prescribed	and	dispensed	systemic	MHT	during	the	study	period.	
MHT	exposure	was	defined	according	to	the	following	ATC-codes:	G03C	(estrogens);	G03D	
(progestogens,	only	included	if	prescribed	in	combination	with	estrogens);	and	G03F	
(progestogens	and	estrogen	in	combination).	MHT	is	used	for	treatment	of	menopausal	
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symptoms	and	prevention	of	osteoporosis,	and	is	recommended	as	estrogen	combined	with	
progestin	in	women	with	an	intact	uterus	(to	reduce	the	risk	of	endometrial	cancer)	or	as	
estrogen	alone	in	women	who	have	undergone	hysterectomy.22-24	Only	systemic	treatments	
were	included,	i.e.,	oral	tablets,	dermal	patches,	and	dermal	gel.		
The	non-exposed	comparison	cohort	consisted	of	women	not	receiving	a	prescription	of	
MHT	during	the	study	period,	older	than	40	years	and	without	a	history	of	any	cancer.	The	
non-exposed	women	were	selected	from	the	nationwide	chemoprevention	cohort,	which	
includes	up	to	95%	of	all	women	in	Sweden	of	this	age	group.	These	participants	were	
frequency-matched	to	mimic	the	MHT-users	on	the	distribution	of	the	variables	age,	parity,	
hysterectomy,	thrombotic	events,	diabetes,	obesity,	smoking-related	diseases,	and	alcohol-
related	diseases.		
	
Outcomes	
Esophageal	cancer	was	identified	using	the	International	Classification	of	Diseases	version	7	
(ICD-7)	anatomical	codes	150	(esophagus)	or	1511	(cardia),	and	histological	codes	096	for	
adenocarcinoma	and	146	for	squamous	cell	carcinoma	in	the	Cancer	Register.	Gastric	cancer	
was	identified	using	the	ICD-7	anatomical	codes	1510,	1518,	or	1519,	and	the	histological	
code	096	was	used	only	to	define	adenocarcinoma.25	Patients	with	unspecified	histological	
types	of	cancer	were	excluded	from	the	analyses.	
	
Confounders		
Ten	potential	confounding	factors	were	considered.	First,	we	included	only	participants	
without	a	history	of	any	cancer	(to	avoid	bias	from	detection	or	influence	of	cancer	
treatments).	The	ever-users	of	MHT	were	matched	to	the	non-users	to	select	a	group	of	
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non-users	as	similar	as	possible	to	the	users	regarding	eight	a	priori	selected	factors.	Group-
level	(i.e.,	frequency)	matching	was	used,	aiming	for	a	1:3	ratio	with	exact	matching	on	
three	binary	variables:	parity	(ever-parous	or	non-parous,	increased	life	time	exposure	to	
estrogen),	hysterectomy	(leading	to	earlier	contact	with	gynecologist,	and	influencing	the	
choice	of	what	MHT	treatment	to	use),	and	thrombotic	events	(contraindication	for	MHT).26	
Nearest	neighbor	matching	was	done	for	another	five	variables:	age	(a	risk	factor	for	cancer,	
determined	from	exact	date	of	birth),	diabetes	mellitus	(a	proxy	for	obesity),	obesity	(which	
might	influence	the	probability	of	receiving	MHT,	and	is	a	risk	factor	for	the	studies	cancers),	
smoking-related	diseases	(a	proxy	for	smoking,	which	might	influence	both	the	probability	
of	receiving	MHT	and	the	cancer	risk),	and	alcohol-related	diseases	(a	proxy	for	high	alcohol	
consumption,	which	might	influence	both	the	probability	of	receiving	MHT	and	the	cancer	
risk).26	The	used	matching	method	aims	for	as	close	to	an	exact	match	on	all	the	included	
variables	to	reduce	baseline	imbalances.	Finally,	after	the	matching	procedure	was	
completed,	osteoporosis	was	added	and	adjusted	for	in	the	analysis	(since	this	is	an	
indication	for	treatment	with	MHT).23	All	codes	defining	the	comorbidities	are	presented	in	
the	Supplementary	Table	1.	If	an	individual	lacked	a	certain	diagnosis	code,	this	diagnosis	
was	interpreted	as	absent.	
	
Statistical	analysis	 	
The	cancer	risk	was	assessed	in	a	conditional	logistic	regression	model,	taking	into	account	
the	clustering	by	the	exact	matching	variables,	as	well	as	also	adjusting	for	all	the	potential	
confounders.	Due	to	the	study	design,	follow-up	time	for	the	non-users	is	not	calculated,	
nor	used	in	the	analyses.	The	results	were	presented	as	odds	ratios	(OR)	with	95%	
confidence	intervals	(CI).	Subgroup	analyses	were	conducted	based	on	the	regimen	of	MHT	
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(estrogen	only	or	estrogen	combined	with	progestin)	and	age	groups	(year	of	birth	before	
1943,	1943-1951,	or	in	1952	or	later).	The	age	groups	were	defined	based	on	the	
recommended	ages	for	MHT	use,	i.e.	recommended	for	women	aged	younger	than	60	years	
and	not	recommended	for	women	aged	older	than	70	years.27	Poisson	regression	was	
conducted	when	comparing	≤12	months	duration	of	MHT	treatment	with	>12	months	
duration.	
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RESULTS	
Participants	
The	study	included	290,186	ever-users	of	MHT	and	870,165	matched	non-users	of	MHT.	Of	
the	ever-users,	135,988	(46.9%)	dispensed	estrogen	only	MHT,	and	154,198	(53.1%)	
dispensed	a	combination	of	estrogen	and	progestin	MHT.	The	ever-users	and	non-users	
were	similar	regarding	the	prevalence	of	all	matching	variables	(Table	1).	The	median	follow-
up	time	among	the	users	of	MHT	was	7.0	years	(2540	days),	and	the	interquartile	range	was	
4.1-7.4	years	(1487-2685	days).			
	
Risk	of	esophageal	adenocarcinoma	
Among	the	ever-users	of	MHT,	46	(0.02%)	developed	esophageal	adenocarcinoma,	while	
224	(0.03%)	such	cases	occurred	among	non-users	(Table	1).	The	adjusted	OR	of	esophageal	
adenocarcinoma	was	38%	lower	among	ever-users	compared	to	non-users	(OR	0.62,	95%	CI	
0.45-0.85)	(Table	2).	Among	users	of	estrogen	only	MHT,	the	corresponding	OR	was	0.57	
(95%	CI	0.37-0.87),	while	the	OR	among	women	receiving	estrogen	and	progestin	combined	
MHT	was	0.70	(95%	CI	0.45-1.09).	In	MHT-users	younger	than	60	years,	the	OR	of	
esophageal	adenocarcinoma	was	particularly	decreased	(OR	0.20,	95%	CI	0.06-0.65),	while	
the	ORs	were	less	decreased	in	MHT-users	aged	60-70	years	(OR	0.60,	95%	CI	0.34-1.07)	and	
those	older	than	70	years	(OR	0.79,	95%	CI	0.52-1.19)	(Table	3).	The	statistical	power	was	
insufficient	to	allow	analyses	examining	duration	of	MHT.	
	
Risk	of	gastric	adenocarcinoma	
11	
	
There	were	123	(0.04%)	new	cases	of	gastric	adeoncarcinoma	among	the	ever-users	of	MHT	
and	608	(0.07%)	cases	among	the	non-users	(Table	1).	Comparing	ever-users	with	non-users,	
the	overall	adjusted	OR	of	gastric	adenocarcinoma	was	0.61	(95%	CI	0.50-0.74)	(Table	2).	
Ever-users	of	estrogen	only	MHT	(OR	0.60,	95%	CI	0.47-0.76)	and	of	estrogen	and	progestin	
combined	MHT	(OR	0.64,	95%	CI	0.48-0.87)	had	decreased	ORs	of	similar	strength.	The	OR	
of	gastric	adenocarcinoma	was	particularly	decreased	in	MHT-users	younger	than	60	years	
(OR	0.39,	95%	CI	0.21-0.71),	and	less	so	in	those	of	60-70	years	of	age	(OR	0.69,	95%	CI	0.48-
0.98),	and	in	MHT-users	older	than	70	years	(OR	0.63,	95%	CI	0.49-0.81)	(Table	3).	When	
comparing	≤12	months	duration	of	MHT	with	>12	months	the	incidence	rate	ratio	was	0.92	
(95%	CI	0.43-1.97).	
	
Risk	of	esophageal	squamous	cell	carcinoma	
Among	the	ever-users	of	MHT,	33	(0.01%)	developed	esophageal	squamous	cell	carcinoma,	
while	174	(0.02%)	of	the	non-users	developed	this	cancer.	The	overall	adjusted	OR	of	
esophageal	squamous	cell	carcinoma	was	43%	decreased	among	ever-users	(OR	0.57,	95%	
CI	0.39-0.83)	(Table	2).	The	OR	among	women	receiving	estrogen	only	MHT	was	0.71	(95%	
CI	0.46-1.09)	and	0.38	(95%	CI	0.19-0.75)	among	women	receiving	estrogen	and	progestin	
combined	(Table	2).	The	OR	was	0.80	(95%	CI	0.26-2.44)	in	MHT-users	younger	than	60	
years,	0.41	(95%	CI	0.20-0.82)	in	users	aged	60	to	70	years,	and	0.65	(95%	CI	0.40-1.05)	in	
MHT-users	older	than	70	years	(Table	3).	Comparing	duration	≤12	months	with	>12	months,	
of	MHT	treatment	rendered	an	incidence	rate	ratio	of	0.45	(95%	CI	0.11-1.79).	
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DISCUSSION	
In	this	study,	ever-users	of	MHT	were	at	a	decreased	risk	of	esophageal	adenocarcinoma,	
gastric	adenocarcinoma,	and	esophageal	squamous	cell	carcinoma.	The	estrogen	only	MHT-
users	had	a	decreased	risk	of	esophageal	and	gastric	adenocarcinoma	in	particular,	while	
women	using	combined	therapy	with	estrogen	and	progestin	may	be	at	a	particularly	
decreased	risk	of	esophageal	squamous	cell	carcinoma.	For	esophageal	and	gastric	
adenocarcinoma,	a	strongly	decreased	risk	following	MHT	use	was	found	among	younger	
women.		
	
Strengths	of	this	study	include	the	complete	nationwide	coverage	with	a	large	sample	size,	
the	completeness	of	the	follow-up,	and	the	validity	of	the	data	contained	in	the	Swedish	
registers	used.	The	linkage	of	data	between	registers	using	the	personal	identity	numbers	
available	in	all	Swedish	residents	was	a	prerequisite	for	this	study.15	The	Prescribed	Drug	
Registry	contains	all	prescribed	and	dispensed	medications	in	Sweden,	thus	minimizing	the	
risk	of	selection	bias.	The	completeness	and	accuracy	of	the	data	in	the	Cancer	Registry	
guarantees	a	robust	assessment	of	the	study	outcomes.16-18	There	are,	however,	also	
limitations	of	the	study.	Confounding	is	a	threat	to	observational	studies	in	general.	We	
could	not	take	into	account	potential	influence	of	breastfeeding	and	other	reproductive	
factors,	including	age	at	menopause	or	number	of	pregnancies	and	deliveries,	factors	that	
may	affect	the	lifetime	cumulative	estrogen	exposure.	There	is	also	a	possibility	that	women	
using	MHT	differ	from	women	not	having	such	treatment	in	terms	of	lifestyle	factors	that	in	
turn	affect	the	risk	of	the	studied	cancers.	However,	the	study	controlled	for	10	potential	
confounders	which	should	have	counteracted	confounding,	which	creates	a	comparison	
group	as	similar	as	possible	to	the	exposed	group	at	baseline.	The	matching	on	key	factors	
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mimics	a	randomization	on	the	selected	factors.	Since	some	of	the	confounding	factors	were	
recorded	to	only	a	limited	degree	in	the	registers,	e.g.	obesity	and	diabetes,	the	matching	
strategy	is	ideal.	No	validation	study	of	obesity	diagnosis	in	the	Swedish	Patient	Registry	has	
been	conducted	till	today,	although	obesity	is	believed	to	be	substantially	underreported.	
The	coding	for	diabetes	mellitus	(type	1	and	2)	in	the	Swedish	Patient	Registry	has	been	
found	to	have	high	validity	in	previous	studies.20	Smoking	and	alcohol	consumption	were	
assessed	indirectly,	based	on	smoking-related	diseases	and	alcohol-related	diseases.	
Although	this	does	not	represent	the	true	incidence	of	smoking	and	excessive	alcohol	
consumption,	it	should	detect	the	most	severe	and	long-term	consumers.	We	did	not	adjust	
for	gastroesophageal	reflux	disease	or	Helicobacter	pylori,	the	risk	factors	for	esophageal	
adenocarcinoma	and	gastric	adenocarcinoma,	respectively.1,	7	However,	estrogen	therapy	is	
rather	associated	with	an	increased	risk	of	reflux,	and	could	therefore	not	explain	the	
negative	association	between	MHT	and	esophageal	adenocarcinoma.28	MHT	use	is	unlikely	
to	be	associated	with	Helicobacter	pylori,	and	thus	should	not	act	as	a	confounder.29	A	
weakness	was	the	lack	of	starting	dates	of	MHT	use	for	women	enrolled	in	the	cohort	in	July	
2005	(start	of	the	study),	which	prohibited	an	assessment	of	duration	of	MHT	use	in	relation	
to	cancer	risk.	The	lack	of	information	on	MHT	use	before	2005	resulted	in	a	possibility	that	
women	might	have	received	MHT	before	the	initiation	of	the	study,	which	could	lead	to	
women	using	MHT	before	the	initiation	of	the	registration	were	included	in	the	non-
exposed	cohort.	However,	such	exposure	misclassification	is	likely	to	be	at	random	and	
would	thus	dilute	the	ORs	rather	than	explaining	the	decreased	ORs.	Further,	due	to	the	
current	design	and	statistical	analyses	a	sensitivity	analysis	is	not	possible	since	no	proxy	
date	of	entry	is	assigned	to	the	non-users,	meaning	that	only	cases	among	users	can	be	
excluded	from	the	first	year	of	inclusion	in	the	study.	Finally,	a	longer	follow-up	than	about	
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8	years	would	have	been	preferable	when	studying	cancer	risk.	Yet	the	study	is	the	largest	
cohort	investigating	the	association	between	MHT	and	risk	of	esophageal	and	gastric	cancer.		
	
The	study	hypothesis	was	based	on	the	unexplained	strong	male	predominance	in	
esophageal	adenocarcinoma	and	moderate	male	predominance	in	gastric	adenocarcinoma,	
which	we	thought	would	be	reflected	in	a	reduced	risk	among	MHT-users.	We	thought	the	
already	explained	male	predominance	in	esophageal	squamous	cell	carcinoma,	would	
transfer	into	no	association	with	MHT	use.	We	cannot	entirely	exclude	that	the	reduction	in	
the	risk	of	all	three	cancers	may	indicate	healthy	users	bias,	a	sampling	bias	where	patients	
receiving	MHT	might	differ	from	the	comparison	population,	mainly	differences	in	lifestyle	
behavior.	This	could	among	other	things	be	in	relation	to	smoking	and	alcohol	consumption,	
where	there	might	be	differences	between	different	age	groups,	which	could	reflect	in	the	
different	ORs	for	different	age	groups	in	relation	to	MHT	prescription.	The	lack	of	any	
increased	risk	of	gastric	adenocarcinoma	or	esophageal	squamous	cell	carcinoma	with	
longer	duration	of	MHT	argues	in	favor	of	non-hormonal	influence.	However,	the	matching	
on	many	health-related	factors	intended	to	counteract	such	bias,	and	the	results	of	this	
study	are	well	in	line	with	all	three	meta-analyses	on	the	topic.	These	meta-analyses	have	
found	decreased	risk	estimates	of	esophageal	adenocarcinoma	(odds	ratio	0.75,	95%	CI	
0.58-0.98,	5	studies	included),12	gastric	adenocarcinoma	(risk	ratio	0.77,	95%	CI	0.64-0.92,	7	
studies	included),13	and	esophageal	squamous	cell	carcinoma	(risk	ratio	0.68,	95%	CI	0.48-
0.96,	4	studies	included).14	Moreover,	presence	of	estrogen	receptors	have	repeatedly	been	
found	in	both	esophageal	and	gastric	adenocarcinoma	cells,	and	treatment	with	ligands	
binding	to	selective	estrogen	receptors	could	inhibit	cell	growth	and	induce	apoptosis	in	
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esophageal	adenocarcinoma.30-37	It	has	also	been	suggested	that	sex	hormones	inhibit	cell	
growth	in	gastric	adenocarcinoma	and	esophageal	squamous	cell	carcinoma.38-40		
Progesterone	receptors	have	been	found	in	gastric	adenocarcinoma	in	some	studies	but	to	a	
similar	extent	as	in	normal	mucosa.33,	41-43	Androgen	receptors	have	been	identified	in	
esophageal	adenocarcinoma	and	esophageal	squamous	cell	carcinoma,	while	these	
receptors	have	been	inconsistently	found	in	gastric	adenocarcinoma.43-45	Thus,	sex	
hormonal	influence	might	play	a	key	role	in	explaining	the	findings	of	this	study.		
	
There	is	a	need	for	more	large-scale	studies	with	long	follow-up	and	adjustment	for	lifestyle	
factors	before	a	causal	relation	between	sex	hormonal	therapy	and	cancer	prevention	can	
be	established.	If	the	findings	of	the	current	study	are	supported	by	such	research,	they	
would	encourage	research	examining	new	prevention	strategies	using	sex	hormonal	therapy	
in	high-risk	individuals	of	esophageal	or	gastric	cancers,	and	of	hormonal	adjuvant	therapy	
of	these	tumors.		
	
In	conclusion,	this	large	population-based	cohort	study	with	robust	assessments	of	
exposures	and	outcomes	and	adjustment	for	several	potential	confounding	factors	found	
that	ever-users	of	MHT	are	at	a	decreased	risk	of	esophageal	adenocarcinoma,	gastric	
adenocarcinoma,	and	esophageal	squamous	cell	carcinoma.	These	findings	might	potentially	
be	explained	by	sex	hormonal	effects,	but	this	remains	uncertain,	and	more	research	is	
required	to	examine	the	mechanisms	behind	these	associations.	
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Table	1.	Characteristics	of	ever-users	and	non-users	of	menopausal	hormone	therapy	(MHT).		
	 Ever-users	of	MHT	 Non-users	of	MHT	
	 Number	(%)	 Number	(%)	
Total	 290,186	(100.0)	 870,165	(100.0)	
Age	(in	years)	 	 	<60	 108,631	(37.4)	 325,747	(37.4)	
60-69	 93,490	(32.2)	 267,323	(30.8)	
≥70	 88,065	(30.4)	 277,095	(31.8)	
Follow-up	(years)	 	 	
Median	(Interquartile	range)	 7.0	(4.1-7.4)	 N/A	
Parity	 	 	
Ever-parous	 117,861	(40.6)	 353,282	(40.6)	
Comorbidity	 	 	
Hysterectomy	 51,811	(17.9)	 155,138	(17.8)	
Thrombotic	events	 40,316	(13.9)	 120,931	(13.9)	
Diabetes	mellitus	 15,936	(5.5)	 48,422	(5.6)	
Obesity	 5,146	(1.8)	 15,526	(1.8)	
Smoking-related	diseases	 13,601	(4.7)	 40,994	(4.7)	
Alcohol-related	diseases	 7,293	(2.5)	 21,455	(2.5)	
Osteoporosis	 8,256	(2.9)	 22,764	(2.6)	
Esophageal	or	gastric	cancer	during	follow-up	 	 	
Esophageal	adenocarcinoma	 46	(0.02)	 224	(0.03)	
Esophageal	squamous	cell	carcinoma	 33	(0.01)	 174	(0.02)	
Gastric	adenocarcinoma	 123	(0.04)	 608	(0.07)	
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Table	2.	The	risk	of	esophageal	and	gastric	cancers	following	ever	use	of	different	regimens	of	menopausal	hormone	therapy	(MHT)	
compared	to	non-users,	expressed	as	odds	ratios	(OR)	with	95%	confidence	intervals	(CI).	
		
Non-users	
Number=870,165	
Ever-users	
Number=290,186	
Estrogen	only	users		
Number=135,988	
Estrogen	+	progestin	users		
Number=154,198	
		 Number	(%)	 Number	(%)	 OR	(95%	CI)*	 Number	(%)	 OR	(95%	CI)*	 Number	(%)	 OR	(95%	CI)*	
Esophageal	
adenocarcinoma	 224	(0.03)	 46	(0.02)	 0.62	(0.45-0.85)	 24	(0.02)	 0.57	(0.37-0.87)	 22	(0.01)	 0.70	(0.45-1.09)	
Gastric	
adenocarcinoma	 608	(0.07)	 123	(0.04)	 0.61	(0.50-0.74)	 75	(0.06)	 0.60	(0.47-0.76)	 48	(0.03)	 0.64	(0.48-0.87)	
Esophageal	squamous	
cell	carcinoma	 174	(0.02)	 33	(0.01)	 0.57	(0.39-0.83)	 24	(0.02)	 0.71	(0.46-1.09)	 9	(0.01)	 0.38	(0.19-0.75)	
	
*	Adjusted	for	age,	parity,	hysterectomy,	thrombotic	events,	diabetes	mellitus,	obesity,	smoking-related	diseases,	alcohol-related	diseases,	and	
osteoporosis	(all	but	osteoporosis	were	used	for	matching).	
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Table	3.	The	risk	of	esophageal	and	gastric	cancers	in	ever-users	of	menopausal	hormone	therapy	(MHT)	compared	to	non-users,	
categorized	by	age	group	and	expressed	as	odds	ratios	(OR)	with	95%	confidence	intervals	(CI).	
		 Ever-users	
Number	(%)	
Non-users	
Number	(%)	
OR	(95%	CI)*	
Esophageal	adenocarcinoma		 	 	 	
<60	years	 3	(0.00)	 43	(0.01)	 0.20	(0.06-0.65)	
60-69	years	 14	(0.01)	 67	(0.03)	 0.60	(0.34-1.07)	
≥70	years	 29	(0.03)	 14	(0.00)	 0.79	(0.52-1.19)	
Gastric	adenocarcinoma	 	 	 	
<60	years	 12	(0.01)	 89	(0.03)	 0.39	(0.21-0.71)	
60-69	years	 37	(0.04)	 153	(0.06)	 0.69	(0.48-0.98)	
≥70	years	 74	(0.08)	 366	(0.13)	 0.63	(0.49-0.81)	
Esophageal	squamous	cell	carcinoma		 	 	 	
<60	years	 4	(0.00)	 14	(0.00)	 0.80	(0.26-2.44)	
60-69	years	 9	(0.00)	 63	(0.02)	 0.41	(0.20-0.82)	
≥70	years	 20	(0.02)	 97	(0.04)	 0.65	(0.40-1.05)	
	
*Adjusted	for	age,	parity,	hysterectomy,	thrombotic	events,	diabetes	mellitus,	obesity,	smoking-related	diseases,	alcohol-related	diseases,	and	
osteoporosis	(all	but	osteoporosis	were	used	for	matching	
